Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100970 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Zoran Andric und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Hospital Center Bezanijska Kosa, Belgrade 11000, Serbia. Electronic address: drzoranandric@gmail.com. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biosimilar Pharmaceuticals. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Celltrion Pharm Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Hospital Center Bezanijska Kosa, Belgrade 11000, Serbia. Electronic address: drzoranandric@gmail.com.
- GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology) named after N.P. Napalkov - Hospital, Ulitsa Leningradskaya 68a Litera A, Poselok Pesochny, Saint Petersburg, Leningradskaya oblast…
- LTD "High Technology Hospital Medcenter", 118 Pushkini Street, Batumi 6000, Georgia. Electronic address: tamta.makharadze@gmail.com.
- Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, 40a Vatslava Havela Boulevard, Kyiv 03126, Ukraine. Electronic address: aliona.aleksandrovna92@gmail.com.
- Department of Internal Medicine Oncology Unit - Hematology, School of Medicine, Universidad de la Frontera, Hochstetter 298, Temuco 4800827, Chile. Electronic address: eduardoyanez.sim@gmail.com.
- Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon 22014, Republic of Korea. Electronic address: sunghyun.kim@celltrion.com.
Förderung
- NCI NIH HHS
- Celltrion Pharm Inc
Zitieren
APA
Andric, Z., Moiseenko, F., Makharadze, T., Oleksiienko, A., Yañez Ruiz, E., Kim, S., Ahn, K., Park, T., Ju, H., Baek, E. H., Kwon, S., Chang, I., Kim, S., Kim, H., Lee, E., & Verschraegen, C. (2025). Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100970
Vancouver
Andric Z, Moiseenko F, Makharadze T, Oleksiienko A, Yañez Ruiz E, Kim S, et al. Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100970
BibTeX
@article{Andric2025,
author = {Andric, Zoran and Moiseenko, Fedor and Makharadze, Tamta and Oleksiienko, Alona and Yañez Ruiz, Eduardo and Kim, SungHyun and Ahn, KeumYoung and Park, TaeHong and Ju, Hana and Baek, Eric Hyungseok and Kwon, Soonbum and Chang, IlSung and Kim, SinHye and Kim, HyunAh and Lee, EunKyung and Verschraegen, Claire},
title = {Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100970}
}
EUVIMED